Lead Product(s) : Combretastatin A1 Diphosphate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Oncotelic Announces US Patent Grant for CA4P and OXI4503 Combination With Checkpoint Inhibitors
Details : CA4P means Oncotelic’s proprietary Combretastatin A-4 phosphate a prodrug, is a microtubule destabilizing drug, a type of vascular-targeting agent, a drug designed to damage vasculature of cancer tumors causing central necrosis.
Brand Name : OXi4503
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 11, 2022
Lead Product(s) : Combretastatin A1 Diphosphate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Combretastatin A1 Diphosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Granted Pediatric Disease Designation for OXi-4503
Details : OXi4503 in combination with standard chemotherapy drug cytarabine was generally well tolerated by adult AML patients and a maximum tolerated dose level of OXi4503 was identified as the recommended dose for further clinical development of this novel two-d...
Brand Name : OXi4503
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 16, 2020
Lead Product(s) : Combretastatin A1 Diphosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?